Recently, a second‐generation HAP evofosfamide (TH‐302) has demonstrated favourable outcomes in combination with CTLA‐4 and PD‐1 blockade by curing more than 80% of tumours in a mouse prostate‐derived model. This evidence concerns the gene CTLA4 and neoplasm.